Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), A. John Iafrate(Massachusetts General Hospital), Christina T. Siwak-Tapp(Apple (Israel)), Benjamin Solomon(Peter MacCallum Cancer Centre), Kristin Bergethon(Massachusetts General Hospital), Yung‐Jue Bang(Seoul National University), Keith D. Wilner(Pfizer (United States)), Joni Dy(University of California, Irvine), Robert G. Maki(Memorial Sloan Kettering Cancer Center), James G. Christensen, D. Ross Camidge(University of Colorado Denver), Jeffrey W. Clark(Massachusetts General Hospital), Dong‐Wan Kim(Seoul National University Hospital), Weiwei Tan(Memorial Sloan Kettering Cancer Center), Eunice L. Kwak(Harvard University), Ravi Salgia(City Of Hope National Medical Center)
Journal of Thoracic Oncology
April 15, 2011
10.1097/jto.0b013e31821528d3
Cited by 439

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k